1.61
前日終値:
$1.44
開ける:
$1.45
24時間の取引高:
1.75M
Relative Volume:
3.05
時価総額:
$66.41M
収益:
$68.68M
当期純損益:
$-60.84M
株価収益率:
-1.0063
EPS:
-1.6
ネットキャッシュフロー:
$-38.42M
1週間 パフォーマンス:
-1.83%
1か月 パフォーマンス:
+11.03%
6か月 パフォーマンス:
-7.47%
1年 パフォーマンス:
-80.34%
Pulmonx Corp Stock (LUNG) Company Profile
Compare LUNG vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
LUNG
Pulmonx Corp
|
1.61 | 59.40M | 68.68M | -60.84M | -38.42M | -1.60 |
|
ABT
Abbott Laboratories
|
111.04 | 196.53B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
370.50 | 146.14B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
93.01 | 122.74B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
72.99 | 107.15B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
83.89 | 49.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-31 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2025-03-10 | 開始されました | D. Boral Capital | Buy |
| 2024-12-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-06-04 | 開始されました | Lake Street | Buy |
| 2024-02-23 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | 開始されました | Craig Hallum | Buy |
| 2023-02-27 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-12-12 | アップグレード | Citigroup | Neutral → Buy |
| 2022-07-11 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-03-02 | 再開されました | BofA Securities | Neutral |
| 2021-12-08 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | 開始されました | Citigroup | Buy |
| 2021-03-25 | 開始されました | Piper Sandler | Neutral |
| 2021-03-10 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-01-04 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-10-26 | 開始されました | BofA Securities | Buy |
| 2020-10-26 | 開始されました | Canaccord Genuity | Buy |
| 2020-10-26 | 開始されました | Morgan Stanley | Equal-Weight |
| 2020-10-26 | 開始されました | Stifel | Buy |
| 2020-10-26 | 開始されました | Wells Fargo | Equal Weight |
すべてを表示
Pulmonx Corp (LUNG) 最新ニュース
LUNG: Analyst Jason Kolbert Maintains 'Buy' Rating with $14 Targ - GuruFocus
Pulmonx (NASDAQ:LUNG) Given "Buy" Rating at D. Boral Capital - MarketBeat
Pulmonx Secures $60 Million Senior Secured Term Loan From Perceptive; $40 Million Drawn - TradingView
Pulmonx Corp (LUNG) Q4 2025 Earnings Call Highlights: Strategic - GuruFocus
Pulmonx (NASDAQ:LUNG) Insider Sells $11,056.76 in Stock - MarketBeat
Pulmonx Q4 Earnings Call Highlights - Yahoo Finance
Pulmonx Corporation (LUNG) Posts Fourth Quarter Loss, Surpasses Revenue Projections - Bitget
Pulmonx closes $60M credit facility with Perceptive Advisors - Investing.com
Pulmonx closes $60 million credit facility with Perceptive - Investing.com
Earnings call transcript: Pulmonx Q4 2025 EPS beats, revenue misses, stock dips - Investing.com Australia
Pulmonx Corporation (LUNG) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Pulmonx (LUNG) Exceeds Q4 Revenue Expectations with Strategic Gr - GuruFocus
Pulmonx (LUNG) Projects 2026 Financial Outlook with Revenue and Margin Targets - GuruFocus
Pulmonx earnings beat by $0.14, revenue fell short of estimates - Investing.com
Pulmonx Corporation Reports Fourth Quarter and Full Year 2025 Financial Results, Highlights Transition and Strategic Focus for 2026 - Quiver Quantitative
Earnings Summary: Pulmonx Q4 - Benzinga
Lung device maker Pulmonx trims losses, guides 2026 sales to $90–92M - Stock Titan
Pulmonx Announces Closing of up to $60 Million Credit Facility - Yahoo Finance
Earnings Preview For Pulmonx - Benzinga
LUNG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LUNG Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
LUNG Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Pulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Bitget
Analyst Jason Kolbert Maintains Buy Rating for Pulmonx (LUNG) at $14 Target | LUNG Stock News - GuruFocus
Pulmonx's (LUNG) "Buy" Rating Reiterated at D. Boral Capital - MarketBeat
Pulmonx Corporation to Announce Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 - Quiver Quantitative
Pulmonx Stock Pops on Takeover Deal: Cash Exit or Hold Out? - AD HOC NEWS
Pulmonx Corporation (NASDAQ:LUNG) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Will Pulmonx Corporation stock outperform Dow Jones index2025 Biggest Moves & Daily Growth Stock Investment Tips - mfd.ru
Pulmonx Stock Under Pressure: Can A Niche Lung-Health Innovator Breathe New Life Into Its Shares? - AD HOC NEWS
Will Pulmonx Corporation stock beat EPS estimatesWeekly Risk Summary & Stock Portfolio Risk Control - mfd.ru
Pulmonx (LUNG) Expected to Announce Earnings on Wednesday - Defense World
Merger Talk: Is Pulmonx Corporation a good ESG investment2025 Key Highlights & Free Community Consensus Stock Picks - baoquankhu1.vn
Pulmonx Aktie: Zahlen im Fokus - Börse Global
Pulmonx Q4 2025 Results: A Litmus Test for New Leadership - AD HOC NEWS
Sentiment Watch: Is Pulmonx Corporation a turnaround story2025 Technical Patterns & Weekly Top Gainers Alerts - baoquankhu1.vn
US Market Wrap: Can Cabaletta Bio Inc disrupt its industryJuly 2025 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Analyzing Pulmonx (NASDAQ:LUNG) and Privia Health Group (NASDAQ:PRVA) - Defense World
Aug Rallies: How Pulmonx Corporation stock compares to growth peersJuly 2025 Gainers & Reliable Volume Spike Alerts - Bộ Nội Vụ
Why The Pulmonx LUNG Narrative Is Shifting After Target Cut And Leadership Return - Yahoo Finance
Is Pulmonx Corporation stock vulnerable to regulatory risks2025 Price Targets & Weekly High Potential Alerts - Улправда
How Pulmonx Corporation stock valuations compare to rivalsTrade Performance Summary & AI Driven Stock Price Forecasts - Улправда
Pulmonx Corporation (NASDAQ:LUNG) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Pulmonx Corporation (NASDAQ:LUNG) Given Consensus Rating of “Hold” by Brokerages - Defense World
How Leadership Changes And Analyst Revisions Are Shaping Pulmonx's Valuation Story - Yahoo Finance
Pulmonx (NASDAQ:LUNG) Trading Up 2.5%Here's What Happened - MarketBeat
EBITDA per share of Pulmonx Corp. – GETTEX:4NI - TradingView — Track All Markets
What technical charts say about Pulmonx Corporation stockWeekly Stock Summary & AI Enhanced Trade Execution Alerts - Улправда
Why Pulmonx Corporation stock is in analyst buy zoneJuly 2025 PreEarnings & AI Driven Stock Reports - Улправда
Can Pulmonx Corporation stock hit analyst price targetsDay Trade & Reliable Price Action Trade Plans - Улправда
How strong is Pulmonx Corporation stock revenue growthQuarterly Trade Report & Short-Term High Return Ideas - Улправда
Pulmonx Corp (LUNG) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):